Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, today announced an oral presentation of Phase 1 DF1001 Monotherapy Dose Escalation Results scheduled on Sunday June 4, from 11:45 - 11:57 a.m.
An oral presentation titled “Phase 1/2 Study of DF1001, an Immune Modulating TriNKET® Targeting HER2, in Patients with Advanced Solid Tumors: Phase 1 DF1001 Monotherapy Dose Escalation Results” will be provided by Howard Safran, MD during the ASCO Developmental Therapeutics – Immunotherapy Session on June 4th. WALTHAM, Mass., June 2, 2023 /PRNewswire/ -- Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, today announced an oral presentation of Phase 1 DF1001 Monotherapy Dose Escalation Results scheduled on Sunday June 4, from 11:45 - 11:57 a.m. The presentation will be in the Arie Crown Theater at the McCormick Place Convention Center in Chicago for the ASCO 2023 Annual Meeting. The presentation, ASCO Abstract 2508, will be given by Howard P. Safran, MD, Chief of Hematology/Oncology at the Lifespan Cancer Institute and Medical Director for the Brown University Oncology Group. Dr. Safran is a lead investigator on the Phase 1/2 clinical trial for the DF1001 TriNKET®, a first-in-human study exploring the safety, tolerability, and preliminary biological and clinical activity of DF1001, an immunotherapy targeting HER2 in patients with advanced solid tumors. “We look forward to presenting our DF1001 Phase 1 study results at ASCO,” said Joseph Eid, MD, President of Research and Development at Dragonfly Therapeutics. DF1001 is a first-in-class immune modulating TriNKET targeting HER2 that drives immune activation in solid tumors. DF1001 is also being evaluated in combination with nivolumab or nab paclitaxel. Clinical trial sites are open in the U.S., France, Belgium, Denmark and The Netherlands. Additional information about the trial, including eligibility criteria, can be found at: https://clinicaltrials.gov (ClinicalTrials.gov Identifier: NCT04143711). About DF1001 About Dragonfly For more information visit: DRAGONFLY MEDIA CONTACT: View original content to download multimedia:https://www.prnewswire.com/news-releases/dragonfly-therapeutics-to-present-phase-1-df1001-monotherapy-dose-escalation-results-at-asco-2023-annual-meeting-301840855.html SOURCE Dragonfly Therapeutics, Inc. |